What happened?
In a nationally representative sample of 9,476 US adults with a first‑degree family history of cancer (representing ~72.6 million people), 50% reported ever discussing family cancer risk with a clinician and 7.8% reported undergoing genetic testing. Testing was 12.9% among those reporting discussion versus 2.7% without; clinician discussion was associated with higher odds of testing (AOR 5.35, 95% CI 4.23–6.76). Overall testing remained low.
Why does it matter?
Family history guides identification of hereditary cancer risk and potential preventive care. The strong association suggests clinician discussion is a potentially modifiable interaction that may increase referral to genetic services and testing, though the cross‑sectional design cannot establish causation.
How to interpret the evidence
This analysis uses US 2023 NHIS data and is nationally representative for the US adult population with first‑degree family cancer history. Measures were self‑reported and NHIS does not distinguish germline from tumour or direct‑to‑consumer tests, creating material uncertainty. Applicability to EU or Malta depends on local service availability, referral pathways and testing policies and is not assumed.
What remains uncertain?
The association does not prove that clinician discussion causes testing or that testing is appropriate for every person with family history. This report does not address specific tests, clinical indications, approvals or local availability, and is not personalised medical advice.
Medical News provides general health education. Individual treatment decisions depend on your circumstances and the advice of your clinical team.
This summary was prepared with AI assistance and checked automatically against the linked primary source. It has not been individually reviewed by a clinician.